although
vaccin
success
control
mani
viral
diseas
diseas
like
control
antivir
chemotherapi
concept
antivir
drug
accept
slowli
partli
toxic
mani
earlier
antivir
agent
contrast
develop
antibiot
attempt
develop
antivir
drug
inde
met
varieti
problem
strictli
depend
cellular
metabol
process
virus
possess
limit
intrins
enzym
system
build
block
may
serv
specif
target
drug
moreov
contrari
bacteriostat
compound
effect
antivir
drug
display
consider
specif
antivir
action
also
irrevers
block
viral
synthesi
order
stop
cell
suicid
due
viral
infect
restor
normal
cell
synthesi
vanden
bergh
et
al
addit
inhibit
antivir
agent
must
broad
spectrum
activ
favor
pharmacodynam
properti
immunosuppress
ideal
situat
antivir
drug
check
infect
immun
system
prepar
destroy
last
viru
particl
munro
et
al
point
critic
immunecompromis
ill
aid
cancer
drug
therapi
transplant
cancer
frequent
caus
death
instanc
viral
infect
adjuv
antivir
chemotherapi
vital
circumst
shannon
schabel
mani
viral
infecti
diseas
still
caus
high
mortal
although
antivir
chemotherapi
shown
outstand
progress
antivir
agent
still
requir
emerg
drugresist
virus
treatment
rais
potenti
problem
effect
therapi
furthermor
new
viral
pathogen
may
discov
biolog
activ
substanc
plant
origin
long
known
viral
inhibitor
antivir
compound
may
extract
sourc
higher
plant
variou
reason
explor
consider
less
tradit
one
first
clinic
use
antivir
drug
methylisatinthiosemicarbazon
methisazon
activ
pox
virus
especi
smallpox
viru
methisazon
mgkg
found
inhibit
variola
viru
mice
later
use
success
treat
case
eczema
vaccinatum
treat
prevent
smallpox
kaufman
et
al
ophthalmologist
success
treat
herp
eye
infect
antineoplast
drug
idoxuridin
time
group
chemist
du
pont
chemic
compani
unit
state
investig
antivir
activ
molecul
call
amantadin
activ
influenza
viru
type
rapid
success
nucleosid
analog
cytosin
arabinosid
trifluorothymidin
adenin
arabinosid
found
inhibit
herp
viru
antiherp
activ
new
compound
guanin
acyclovir
detect
j
bauer
wellcom
research
lab
within
decad
group
discov
azidothymidin
zidovudin
first
effect
inhibitor
newli
emerg
hiv
alkaloid
australian
hors
chestnut
castanospermin
austral
isol
also
found
activ
hiv
research
program
detect
isol
antivir
compound
higher
plant
best
carri
multidisciplinari
team
consist
least
pharmacognosist
virologist
antivir
screen
system
meet
requir
good
assay
includ
valid
lack
ambigu
accuraci
reproduc
simplic
reason
cost
moreov
deal
plant
extract
antivir
screen
highli
select
specif
sensit
advis
discrimin
true
antivir
activ
viricid
one
stage
aforement
requir
better
met
vitro
test
prefer
vitro
screen
plant
extract
also
use
bioassay
guid
isol
antivir
activ
compound
plant
extract
antivir
activ
pure
compound
confirm
later
stage
vivo
assay
leven
et
al
vanden
bergh
et
al
one
possibl
strategi
find
new
antiinfect
drug
may
involv
search
compound
chemotherapeut
activ
supplementari
structur
wide
differ
current
use
compound
could
extract
sourc
variou
reason
explor
consider
less
tradit
microorgan
includ
among
other
higher
plant
mitscher
rao
consid
enorm
number
amaz
structur
divers
current
avail
antimicrobi
antivir
activ
plant
constitu
one
might
hope
promis
system
andor
local
act
antiinfect
agent
might
discov
plant
kingdom
vanden
bergh
et
al
vlientinck
et
al
increas
drugresist
virus
treatment
rais
import
issu
effect
treatment
moreov
new
viral
pathogen
might
found
along
line
strong
requir
promptli
access
antivir
medic
moder
cost
minim
side
effect
henceforth
tradit
medicin
ought
investig
novel
antivir
agent
mani
ancient
medica
contain
differ
plant
metabolit
potent
antivir
activ
chattopadhyay
khan
design
new
antivir
drug
potenti
focus
structur
dynam
replic
cycl
variou
infect
caus
virus
suitabl
exampl
invent
acyclovir
hinder
certain
protein
herp
infect
respons
trigger
diseas
ethnomedicin
vast
repositori
structur
divers
extens
bioactiv
serv
huge
sourc
potenti
antivir
drug
signific
number
medicin
plant
ayurveda
tradit
chines
system
medicin
serv
potenti
remedi
decreas
sever
ill
caus
virus
chattopadhyay
et
al
khan
et
al
jadhav
et
al
research
antivir
potenti
plant
first
start
plant
found
effect
influenza
chattopadhyay
naik
numer
screen
studi
conduct
last
year
determin
antivir
efficaci
medicin
plant
use
vitro
vivo
assay
british
colombian
medicin
plant
show
antivir
efficaci
respiratori
syncyti
viru
rsv
corona
viru
influenza
viru
herp
simplex
viru
hsv
mccutcheon
et
al
marin
alga
spirulina
show
antimutagen
immunomodulatori
antivir
activ
chamorro
et
al
interestingli
cyanovirin
n
protein
blue
green
alga
inactiv
bind
clercq
sulfat
polysaccharid
seawe
alga
show
antihiv
antihsv
activ
schaeffer
krylov
plant
kingdom
highli
divers
rang
unicellular
microscop
plant
long
live
huge
tree
screen
everi
plant
individu
part
identif
antivir
compon
huge
task
sever
exampl
plant
antivir
properti
newli
identifi
activ
compound
report
variou
journal
one
exampl
cite
cyanovirin
n
cvn
protein
isol
cyanobacterium
nostoc
ellipsosporum
exhibit
properti
inhibit
infect
also
possess
broadspectrum
activ
phytochem
podophyllotoxin
isol
aqueou
extract
podophyllum
peltatum
l
inhibit
hsv
type
bedow
hatfield
aceton
extract
anoth
plant
phyllanthu
urinaria
also
suppress
yang
et
al
bessong
et
al
report
comparison
variou
plant
individu
part
stem
leav
root
forth
repress
viral
revers
transcriptas
rt
integras
two
basic
enzym
hiv
diseas
compar
extract
fraction
variou
plant
found
nbutanol
fraction
bridelia
micrantha
hochst
exhibit
highest
antirt
activ
also
report
aqueou
extract
root
carissa
eduli
forssk
vahl
plant
grown
kenya
display
noteworthi
activ
hsv
wild
type
resist
strain
tolo
et
al
polyphenolrich
extract
medicin
plant
geranium
sanguineum
l
report
show
strong
antiinfluenza
viru
activ
well
antioxid
radic
scaveng
capac
sokmen
et
al
hepat
b
c
e
virus
lead
caus
preval
viral
hepat
liver
inflamm
despit
fact
present
infect
prompt
intens
diseas
case
type
b
c
uniqu
caus
chronic
infect
plant
belong
genu
phyllanthu
euphorbiacea
famili
extens
use
tradit
remedi
infect
clinic
investig
addit
intend
look
inhibitori
effect
differ
speci
phyllanthu
p
amaru
l
p
niruri
l
p
urinaria
l
wang
et
al
screen
differ
chines
medicin
herb
led
identif
two
potent
plant
extract
duck
hepat
b
viru
name
ardisia
chinensi
pithecellobium
clypearia
similarli
also
led
identif
oenanth
javanica
blume
dc
flavon
ojf
act
strong
inhibitor
hbsag
hbeag
secret
involv
viral
pathogenesi
cell
also
reduc
dhbvdna
level
hbvinfect
duck
model
wang
et
al
strong
preval
hcv
infect
poor
countri
screen
identif
antihcv
potenti
medicin
plant
still
ongo
accord
hussein
et
al
variou
plant
extract
methanol
extract
acacia
nilotica
l
willd
ex
delil
boswellia
carterii
embelia
schimperi
quercu
infectoria
trachyspermum
ammi
l
aqueou
extract
piper
cubeba
l
q
infectoria
syzygium
aromaticum
l
found
possess
signific
inhibitori
activ
hsv
combin
therapi
treat
diseas
ageold
practic
tradit
medicin
sever
plant
mix
togeth
develop
effect
formul
particular
diseas
combin
therapi
also
tri
inhibit
viral
hepat
exampl
chines
herbal
medicin
prepar
liquid
ferment
broth
ganoderma
lucidum
supplement
aqueou
extract
radix
sophora
flavescenti
potent
hepat
b
viru
activ
vitro
vivo
viral
infect
matter
great
concern
planet
plant
broadspectrum
activ
mani
virus
could
evalu
isol
identif
molecul
treat
viral
infect
exampl
glycyrrhizin
bioactiv
compon
licoric
glycyrrhiza
uralensi
fisch
lycorin
isol
lycori
radiata
l
show
strong
antisarscov
activ
initi
use
treat
indic
li
et
al
b
varieti
herbal
prepar
shown
potenti
inhibit
virus
caus
seriou
infect
among
human
measl
virus
olila
et
al
human
rotavirus
hrv
husson
et
al
takahashi
et
al
respiratori
syncyti
viru
rsv
human
rhinovirus
glatthaarsaalmul
et
al
coxsacki
group
virus
evstropov
et
al
su
et
al
neurotrop
sindbi
viru
nsv
pared
et
al
variou
strain
polio
viru
andrighettifrohn
et
al
melo
et
al
one
illustr
atom
investig
heat
water
concentr
stevia
rebaudiana
l
block
section
differ
irresist
serotyp
hrv
permiss
cell
anion
polysaccharid
molecular
weight
uron
acid
noteworthi
sugar
constitu
takahashi
et
al
thu
alkaloid
concentr
haemanthu
albiflo
globul
repress
rna
amalgam
hrv
spread
cell
husson
et
al
contrast
mani
public
antibacteri
antifung
screen
plant
extract
appear
last
decad
far
fewer
antivir
screen
studi
plant
extract
report
due
chiefli
complex
differ
techniqu
involv
research
consequ
requir
knowhow
dedic
multidisciplinari
team
nevertheless
mani
antivir
agent
isol
natur
sourc
partli
complet
character
studi
sever
substanc
emerg
true
antivir
good
chemotherapeut
index
base
viabil
infect
cell
vivo
test
thu
differ
flavon
synthet
deriv
shown
promis
lead
develop
antirhinoviru
drug
van
hoof
et
al
vlientinck
et
al
wherea
spanonin
glycyrrhiz
acid
found
highli
activ
vitro
herp
simplex
pompei
et
al
varizellazost
baba
shijeta
human
immunodefici
virus
ito
et
al
whether
compound
clinic
potenti
therapi
correspond
viral
diseas
remain
determin
vivo
bioavail
pharmacokinet
paramet
subject
futur
studi
problem
drug
resist
state
earlier
side
effect
pharmaceut
industri
look
forward
toward
natur
product
mainli
medicin
plant
extract
sourc
possibl
antivir
agent
approxim
medicin
plant
speci
record
global
treat
myriad
inflict
diseas
polyphenol
alkaloid
flavonoid
saponin
quinon
terpen
proanthocyanidin
lignin
tannin
polysaccharid
steroid
thiosulfon
coumarin
promin
bioactiv
phytochem
observ
combat
viral
infect
harmless
system
human
bodi
select
anthraquinon
anthraquinon
deriv
note
dammaran
saponin
ginsenosid
chikusetsusaponin
chiiii
found
possess
antivir
activ
hsvi
use
vitro
plaqu
elimin
assay
chiiii
prevent
plaqu
format
half
concentr
fukushima
et
al
hudson
tower
inhibitori
effect
ferul
acid
isoferul
acid
murin
product
respons
influenza
viru
infect
vitro
report
hirabayashi
et
al
effect
isoferul
acid
found
greater
ferul
acid
hayashi
et
al
found
direct
inhibitori
activ
steam
distil
prepar
fresh
plant
houttuynia
cordata
saururacea
influenza
viru
without
show
cytotox
polioviru
coxsacki
viru
montanha
et
al
evalu
action
seri
aporphin
alkaloid
cell
cultur
basi
viral
titer
reduct
six
alkaloid
found
activ
ellagitannin
isol
phyllanthu
myrtifoliu
p
urinaria
euphorbiacea
show
activ
epsteinbarr
viru
dna
polymeras
flavonoid
constitu
biflavonoid
robustaflavon
exhibit
strong
inhibitori
effect
influenza
b
virus
antivir
potenti
flavonoid
chamaesyc
thymifolia
report
show
high
cytotox
cell
moder
inhibitori
activ
bovin
viral
diarrhea
viru
amar
et
al
sotanaphun
et
al
isol
sclerocarp
acid
stem
bark
glyptopetalum
sclerocarpum
exhibit
antivir
activ
herp
simplex
viru
type
rhamnan
sulfat
natur
sulfat
polysaccharid
isol
monostroma
latissimum
show
potent
inhibitori
effect
viru
replic
hcmv
vitro
matsus
et
al
test
aqueou
methanol
extract
panamanian
medicin
plant
antihiv
effect
seven
found
moder
inhibitor
hivproteas
enzym
serkedjieva
ivancheva
investig
inhibitori
effect
five
extract
bulgarian
medicin
plant
g
sanguineum
herp
simplex
viru
type
yoosook
et
al
evalu
activ
barleria
lupulina
clinacanthu
nutan
result
suggest
therapeut
potenti
b
lupulina
c
nutan
antivir
activ
variou
water
methanol
solubl
substanc
isol
g
lucidum
hsv
type
influenza
viru
vesicular
stomat
viru
studi
use
cytopath
effect
inhibit
assay
plaqu
reduct
assay
eo
et
al
kudi
myint
investig
antivir
activ
medicin
plant
extract
polioviru
astroviru
hsv
parvoviru
extract
show
activ
one
viru
dose
rate
eo
et
al
bourn
et
al
assess
plant
product
vitro
plaqu
reduct
assay
determin
activ
commonli
transmit
pathogen
herp
simplex
viru
type
docherti
et
al
found
resveratrol
phytoalexin
inhibit
replic
dosedepend
revers
manner
anani
et
al
prepar
methanol
extract
medicin
plant
togo
analyz
antivir
antibiot
activ
ten
show
signific
antivir
activ
one
anoth
test
virus
herp
simplex
sindbi
polioviru
hudson
et
al
b
evalu
ethanol
extract
plant
endem
madagascar
order
determin
potenti
malagasi
plant
sourc
antivir
activ
nine
extract
signific
activ
hsv
wherea
four
activ
sindbi
viru
bioactiv
flavonoid
baicalein
isol
chines
medicin
plant
scutellaria
baicalensi
georgi
show
antivir
properti
use
highspe
countercurr
chromatographi
hsccc
techniqu
li
chen
mani
substanc
includ
flavonoid
phenol
tannin
triterpen
alkaloid
interfer
host
cell
replic
antivir
activ
concentr
exhibit
extracellular
viricid
activ
viricid
includ
flavonoid
tannin
present
foodstuff
might
import
inhibit
viru
replic
picorna
rota
arena
virus
gastrointestin
tract
human
anim
artemisia
capillari
found
possess
activ
potent
cytotox
potenti
fruit
schisandra
chinensi
schizandracea
use
orient
medicin
lignan
identifi
wuweizisu
c
gomisin
n
activ
method
threw
light
mechan
antihepatotox
action
wellknown
compound
glycyrrhizin
intestin
metabolit
protect
first
stage
preced
hepat
lesion
test
type
use
track
activ
substanc
taxu
baccata
potier
group
isol
new
analog
taxol
terpen
compound
display
good
antileukem
antitumor
activ
taxol
promot
polymer
tubulin
microtubul
inhibit
depolymer
choic
among
variou
fraction
obtain
extract
guid
antitubulin
activ
vitro
test
mani
substanc
present
trace
quantiti
difficult
purifi
studi
chemic
exampl
demonstr
xylosebear
deriv
new
seri
compound
regard
structur
activ
relationship
vitro
cytotox
test
shown
activ
mainli
relat
presenc
complex
ester
function
compound
list
plant
extract
phytoconstitu
antivir
potenti
list
tabl
recent
year
lot
develop
taken
place
regard
identif
antivir
molecul
plant
sourc
molecular
mechanist
approach
compound
spiroketalenol
ether
deriv
isol
rhizom
extract
tanacetum
vulgar
report
block
viru
entri
also
arrest
synthesi
gc
gg
glycoprotein
fernand
et
al
samarangenin
b
root
limonium
sinens
exhibit
inhibit
gene
express
kuo
et
al
wherea
oxyresveratrol
artocarpu
lakoocha
plant
found
inhibit
earli
late
phase
viral
replic
respect
chuanasa
et
al
also
pterocarnin
compound
isol
pterocarya
stenoptera
inhibit
bind
penetr
host
cell
co
et
al
structur
potenti
phytoconstitu
signific
antivir
activ
depict
fig
mani
antivir
drug
known
discov
random
search
laboratori
lab
use
biolog
test
system
new
molecul
ad
tissu
cultur
cell
rang
concentr
eg
ml
drugtreat
cell
untreat
cell
control
infect
known
multipl
infect
viru
particl
thousand
compound
inhibit
viral
replic
cell
cultur
gener
complex
regulatori
mechan
viru
easier
find
molecul
inhibit
broad
estim
ratio
activ
antivir
compound
cell
cultur
anim
model
human
evalu
antivir
agent
mani
test
condit
cell
cultur
system
viru
strain
viru
challeng
dose
viru
input
multipl
infect
time
harvest
affect
even
alter
test
result
test
inhibitori
activ
new
antivir
agent
first
necessari
select
host
cell
system
viru
replic
measur
virus
vari
consider
abil
replic
cultur
cell
mani
virus
caus
cpe
form
plaqu
other
produc
special
function
hemagglutin
hemadsorpt
cell
transform
viru
replic
cell
cultur
also
detect
presenc
viral
product
name
viral
dna
rna
polypeptid
antivir
test
select
may
base
inhibit
virusinduc
cytopath
effect
cpe
effect
dose
ed
antivir
agent
express
concentr
inhibit
cpe
half
quadrupl
cultur
b
plaqu
reduct
assay
dose
drug
requir
reduc
plaqu
number
ed
calcul
c
viru
yield
reduct
assay
drug
concentr
requir
reduc
log
reduct
log
reduct
viru
yield
compar
viru
control
infect
cultur
without
drug
determin
doserespons
curv
express
ed
ed
antivir
agent
assay
system
base
measur
special
function
viral
product
number
virus
produc
plaqu
caus
cpe
readili
may
quantifi
certain
special
function
base
uniqu
properti
exampl
hemagglutin
hemadsorpt
test
use
studi
antivir
activ
myxovirus
elisa
use
determin
extent
viru
replic
thu
obtain
measur
inhibitori
effect
variou
antivir
agent
viru
replic
etc
hu
hsiung
colorimetr
assay
quantifi
cell
viabil
enzymemedi
biochem
reaction
owe
ingress
certain
dye
insid
live
cell
mosmann
borenfreund
puerner
first
advoc
applic
tetrazolium
mtt
neutral
red
nr
assay
respect
quantit
cell
viabil
cytotox
cell
vitro
parida
et
al
compar
efficaci
two
colorimetr
assay
mtt
neutral
red
determin
viral
infect
microcultur
viru
titrat
employ
polio
viru
dengu
viru
mtt
assay
also
known
tetrazolium
assay
exploit
extens
reveal
protect
efficaci
therapeut
agent
plant
extract
cancer
hsv
polio
viru
type
viru
determin
neutral
antibodi
level
hiv
respiratori
syncyti
viru
mtt
assay
use
microcultur
viru
titrat
mcvt
appli
determin
infect
titer
influenza
virus
found
compat
wellestablish
procedur
egg
infect
assay
unlik
mtt
neutral
red
dye
uptak
assay
substanti
exploit
virolog
research
nr
dye
assay
earlier
perform
studi
antivir
efficaci
basil
leav
extract
polio
viru
type
mtt
tetrazolium
salt
yellowcolor
dye
bromid
get
clear
mitochondri
succin
dehydrogenas
enzym
bluecolor
formazan
activ
cell
product
form
crystal
interact
isopropyl
alcohol
thu
accur
measur
need
harvest
viabl
cell
wherein
cell
viabil
directli
measur
spectrophotomet
parida
et
al
assay
procedur
discuss
section
colorimetr
assay
base
cleavag
tetrazolium
salt
develop
human
cytomegaloviru
hcmv
antivir
suscept
test
adapt
microtit
plate
format
bedard
et
al
develop
colorimetr
assay
base
cleavag
tetrazolium
salt
human
cytomegaloviru
antivir
suscept
test
respons
differ
cell
cultur
given
antivir
agent
includ
drug
metabol
toxic
among
factor
may
vari
greatli
perform
antivir
test
particular
viru
infect
necessari
obtain
suitabl
host
cell
system
viru
infect
antivir
agent
may
behav
differ
differ
cell
cultur
system
although
viru
strain
use
ii
viru
strain
passag
histori
variabl
sensit
given
antivir
agent
note
among
differ
strain
hsv
cmv
drugresist
strain
emerg
antivir
agent
especi
herp
viru
group
passag
histori
viru
strain
may
also
affect
sensit
antivir
agent
moi
influenc
substanti
evalu
antivir
activ
plaqu
reduct
method
viru
yield
reduct
assay
high
moi
decreas
sensit
viru
antivir
agent
may
also
contribut
dispar
among
antivir
evalu
result
even
viru
moi
kept
constant
hu
hsiung
activ
sever
known
antivir
phytochem
profoundli
affect
presenc
serum
compon
exampl
terthiophen
inhibit
concentrationdepend
manner
serum
case
carboxyl
acid
deriv
compound
appear
antivir
activ
presenc
serum
yet
absenc
compound
effect
contrast
complex
anthraquinon
hypericin
requir
small
amount
serum
maxim
antivir
activ
reaction
also
strongli
affect
order
incub
compon
viru
compound
serum
light
hudson
tower
virus
select
initi
evalu
plant
extract
obvious
major
import
must
chosen
repres
differ
group
virus
accord
morpholog
variou
multipl
mechan
rang
viru
diseas
chemic
control
would
use
besid
need
control
also
preval
viral
diseas
result
project
market
potenti
determin
antigen
abund
caus
virus
problem
repres
vaccin
control
import
select
criteria
grunert
vitro
method
therefor
appropri
allow
simultan
screen
batteri
virus
vivo
screen
extract
broad
array
virus
contrast
expens
also
extrem
labori
vitro
antivir
bioassay
util
thinli
confluent
monolay
tissu
cultur
cell
suffici
suscept
infect
virus
visibl
cytopathogen
effect
cpe
occur
exampl
round
shrink
detach
cell
monolay
produc
readili
observ
microscop
monolay
cell
consist
anim
human
cell
chick
embryo
rabbit
green
monkey
kidney
cell
vero
cell
human
skin
fibroblast
carcinoma
cell
hela
cell
grown
cultur
medium
continu
cell
line
use
virolog
mostli
transform
cell
maintain
indefinit
number
gener
host
cell
requir
appropri
tissu
cultur
medium
surviv
least
week
without
renew
medium
renew
medium
caus
chang
intraand
extracellular
product
alter
viru
concentr
medium
must
stabl
ph
whole
incub
time
may
contain
small
amount
serum
blood
product
tend
absorb
mani
compound
mostli
defin
synthet
medium
supplement
type
serum
fetal
bovin
calf
hors
buffer
sometim
bacteri
fungal
inhibitori
antibiot
use
accord
experi
vero
cell
allow
growth
mani
human
virus
visibl
cpe
grown
medium
describ
hronovoski
et
al
slightli
modifi
lower
pyruv
concentr
suitabl
antivir
screen
plant
extract
van
den
bergh
et
al
mani
combin
test
virus
possibl
batteri
six
virus
seem
quit
accept
viru
type
strain
may
vari
sensit
select
function
abil
multipli
tissu
cultur
cell
cultur
model
use
screen
system
way
object
comparison
antivir
activ
possibl
wherea
toxic
test
minim
moreov
viru
multipl
must
caus
visibl
cpe
within
reason
period
time
prefer
within
week
infect
express
number
infecti
unit
per
volum
infecti
unit
defin
smallest
amount
viru
capabl
produc
reaction
viru
inocul
carri
two
gener
appli
method
name
plaqu
test
pt
endpoint
titrat
techniqu
eptt
plaqu
test
monolay
cell
grown
plastic
glass
petri
dish
inocul
dilut
viral
suspens
adsorpt
infecti
viru
particl
host
cell
monolay
overlaid
agarosecontain
medium
newli
form
viru
particl
local
solid
agar
layer
newli
form
infecti
particl
spread
initi
infect
cell
adjac
cell
develop
wellcircumscrib
foci
cellular
degener
area
dead
cell
call
plaqu
visual
stain
cell
monolay
vital
dye
neutral
red
plaqu
may
also
detect
microscop
determin
multinucl
cell
eg
measl
immunofluoresc
concentr
viral
suspens
measur
count
plaqu
express
plaqueform
unit
per
ml
pfu
ml
endpoint
titrat
techniqu
concentr
infect
measur
determin
highest
dilut
suspens
produc
cpe
cell
cultur
inocul
dilut
call
tissu
cultur
dose
endpoint
tcd
dilut
therefor
made
mainten
medium
certain
volum
ml
ad
four
tube
cultur
proport
posit
cultur
regist
dilut
precis
dilut
inocul
tube
cultur
infect
calcul
dilut
inoculum
contain
averag
one
tcd
one
tissu
cultur
infecti
dose
tissu
cultur
tube
influenc
plant
extract
viru
multipl
determin
viricid
antivir
activ
viricid
activ
measur
titrat
residu
infecti
viru
incub
plant
extract
viru
suspens
least
tcd
ml
hand
antivir
activ
determin
compar
viru
titer
infect
cell
cultur
mainten
medium
contain
plant
extract
test
substanc
mainten
medium
without
test
materi
coleg
molyneux
contrast
antibacteri
screen
solvent
physiolog
buffer
solut
ideal
use
vitro
antivir
screen
plant
extract
sampl
ad
tissu
cultur
cell
observ
mani
nonpolar
plant
extract
prepar
evapor
reason
solubl
dimethyl
sulfoxid
dmso
especi
littl
water
present
sampl
dissolv
sampl
heat
water
bath
viricid
antivir
determin
may
carri
test
solut
contain
dmso
respect
therefor
dissolv
sampl
nonpolar
plant
extract
dmso
ad
dropwis
mainten
medium
ratio
stir
alreadi
mention
mainten
medium
may
contain
antibiot
penicillin
g
ml
neomycin
ml
amphotericin
b
ml
order
avoid
steril
test
solut
contamin
bacteria
fungi
would
inde
ruin
vitro
antivir
bioassay
coleg
molyneux
variou
method
valid
antivir
activ
major
techniqu
highlight
preced
section
fig
current
use
antisept
disinfect
kill
pathogen
bacteria
fungi
within
min
present
concentr
titer
reduct
notic
prepar
fail
kill
pathogen
virus
circumst
method
develop
test
vitro
viricid
effect
plant
extract
describ
follow
section
thoroughli
mix
preincub
plant
extract
dissolv
physiolog
buffer
twofold
dilut
eg
volum
preincub
viru
suspens
exampl
pfu
ml
tcd
ml
physiolog
buffer
incub
mixtur
min
stop
incub
addit
volum
icecold
mainten
medium
filter
mixtur
immedi
filter
elimin
possibl
precipit
filter
icecold
filtrat
filter
concentr
residu
viru
filter
separ
viru
possibl
cytotox
plant
compon
pass
filter
remov
residu
viru
filter
mainten
medium
supplement
serum
ml
sonic
icebath
titrat
dilut
plaqu
format
microtit
plate
accord
eptt
carri
viru
control
physiolog
buffer
contain
plant
extract
simultan
essenti
step
methodolog
separ
cytotox
plant
compon
residu
viru
measur
cytotox
substanc
greater
influenc
activ
extracellular
viru
step
howev
omit
plant
extract
test
toxic
host
cell
condit
evalu
procedur
coleg
molyneux
eptt
techniqu
perform
preempti
confluent
monolay
vero
cell
grown
hole
microtit
plate
infect
serial
dilut
viru
suspens
start
monolay
contain
cell
per
hole
viru
suspens
exampl
tcid
ml
pfu
ml
infect
first
monolay
cell
multipl
infect
moi
antivir
activ
express
viru
titer
reduct
maxim
nontox
dose
mntd
test
substanc
highest
concentr
ml
affect
monolay
antivir
test
condit
viral
titer
reduct
factor
ratio
viral
titer
reduct
absenc
viru
control
presenc
mntd
test
sampl
indic
pronounc
antivir
activ
suitabl
select
criteria
investig
plant
extract
coleg
molyneux
eptt
suitabl
test
complex
sampl
plant
extract
mani
reason
first
concentr
mani
compound
extract
remain
constant
consequ
proport
toxic
versu
activ
compound
chang
ii
second
exact
durat
antivir
action
determin
use
eptt
action
start
moment
extract
ad
cell
iii
third
eptt
use
serial
dilut
extract
deal
dynam
process
cell
subsequ
infect
differ
moi
iv
system
allow
correl
possibl
moi
valu
microtit
plate
decreas
amount
plant
extract
noncytotox
concentr
plant
extract
determin
time
correl
extract
toxic
antivir
activ
accord
correspond
moi
determin
microtit
plate
v
state
gener
rule
detect
antivir
activ
stabl
least
two
subsequ
dilut
nontox
concentr
extract
otherwis
activ
directli
correl
toxic
extract
viricid
moreov
true
antivir
product
protect
cell
infect
low
viru
dilut
start
pfu
per
cell
onward
vi
final
stress
possibl
step
viru
manipul
complet
plant
extract
ad
mean
antivir
product
tcd
ml
nontox
condit
must
act
viru
replic
step
uncoat
cell
complet
protect
lower
moi
tcd
ml
replic
process
uncoat
may
involv
import
aspect
inhibit
viral
cytopath
effect
cpe
determin
tcid
tissu
cultur
infect
dose
harvest
dilut
viru
stock
add
ml
dilut
well
microtit
plate
add
ml
cell
suspens
cellswel
incub
co
atmospher
observ
vial
cpe
altern
day
take
final
read
fifth
day
calcul
tcid
per
method
reed
muench
tcid
calcul
log
valu
antivir
drug
inhibit
cpe
viru
therefor
detect
antivir
agent
amount
inhibit
cpe
viru
observ
microscop
kenni
et
al
purpos
trypsinis
monolay
allow
seed
microtit
plate
incub
wash
monolay
well
add
differ
test
drug
dilut
incub
h
wash
cell
cultur
inocul
ml
tcid
tcid
tcid
viru
suspens
differ
well
incub
h
incub
adsorpt
viru
onto
cell
incub
remov
excess
viru
suspens
wash
rpmi
add
ml
select
concentr
test
compound
keep
viru
cell
control
well
ml
rpmi
contain
sheep
serum
observ
plate
microscop
everi
h
viru
control
show
cpe
tabul
result
hu
hsiung
trypsin
cell
monolay
allow
seed
microtit
plate
incub
h
co
atmospher
remov
medium
wash
cell
monolay
rpmi
without
serum
add
ml
differ
viru
suspens
differ
well
contain
cell
layer
incub
h
viru
adsorpt
wash
excess
viru
suspens
adsorpt
well
add
select
concentr
test
drug
dilut
rpmi
contain
sheep
serum
viru
control
cell
control
rpmi
ad
serum
incub
h
freez
plate
thaw
room
temperatur
coupl
time
liber
associ
viru
determin
viru
titer
end
point
dilut
method
express
tcid
cinatl
et
al
trypsin
monolay
cultur
allow
seed
microtit
plate
incub
wash
monolay
well
add
differ
test
drug
dilut
incub
h
wash
cell
cultur
inocul
ml
tcid
tcid
tcid
viru
suspens
differ
well
incub
h
co
incub
adsorpt
viru
onto
cell
incub
remov
excess
viru
suspens
wash
rpmi
without
serum
add
ml
select
concentr
test
compound
keep
viru
cell
control
well
ml
rpmi
contain
sheep
serum
incub
plate
h
h
discard
old
media
cell
cultur
add
mgml
mtt
bromid
well
incub
h
h
incub
discard
mtt
add
isopropyl
alcohol
cultur
set
asid
min
record
absorb
use
elisa
plate
reader
nm
experi
effect
test
drug
mitochondri
synthesi
due
viral
infect
studi
plaqu
confin
region
contamin
cell
form
multipli
viru
particl
plaqu
reveal
either
region
deaddecim
cell
recogn
cell
stain
zone
pollut
cell
immunostain
blend
cell
monolay
infect
dilut
viral
plaqueform
unit
pfu
absenc
presenc
test
drug
permit
adsorb
h
co
afterward
cell
wash
twice
prewarm
tcid
cpe
dilut
next
cpe
dilut
nex
cpe
dilut
next
minimum
essenti
medium
mem
overlaid
drug
dilut
arrang
overlay
medium
contamin
cultur
without
test
drug
ml
carboxi
methyl
cellulos
ad
ml
medium
plate
incub
day
settl
formalin
formaldehyd
min
cell
stain
methylen
blue
mlwell
gem
violet
wv
wash
dri
check
plaqu
dark
area
lowpow
amplif
binocular
microscop
antivir
impact
measur
percentag
inhibit
plaqu
format
concentr
test
drug
requir
exert
viru
inhibit
ic
ec
compar
infect
control
evalu
graphic
plot
doserespons
curv
regress
analysi
virus
exampl
influenza
agglutin
rbc
due
surfac
ha
protein
analyz
visual
blend
viral
dilut
rbc
util
inspect
inhibitori
impact
medic
ha
serial
dilut
test
drug
use
alongsid
dilut
viral
stock
dilut
mlwell
ad
drugcontain
well
preincub
min
mix
rbc
pb
sampl
solut
specif
dilut
viral
particl
possibl
lose
capac
agglutin
rbc
show
linkag
drug
viral
ha
known
quantiti
viru
moi
use
infect
untreat
drugtreat
cell
allow
adsorb
min
unabsorb
viru
particl
wash
fresh
media
ad
incub
h
cell
wash
pb
fix
paraformaldehyd
permeabil
aceton
triton
cell
wash
block
bovin
serum
albumin
bsa
pb
min
cell
incub
mous
rabbit
antibodi
specif
viral
protein
h
cell
subject
repeat
wash
incub
fluorescenttag
secondari
antibodi
h
wash
wash
cell
visual
fluoresc
microscop
compar
fluoresc
untreat
drugtreat
cell
hand
quantit
cell
trypsin
treatment
fix
paraformaldehyd
cell
wash
permeabil
label
fluorescenttag
antibodi
follow
propidium
iodid
pi
mgml
pb
cell
count
fluorescentactiv
cell
counter
quantit
fluoresc
percentag
known
quantiti
viru
moi
use
infect
untreat
drugtreat
cell
adsorb
h
wash
incub
day
evalu
inhibit
virusinduc
cytopath
effect
cpe
viru
stock
centrifug
freez
thaw
dilut
elisa
well
plate
coat
virusspecif
antibodi
mix
ml
control
test
drug
incub
room
temperatur
h
horseradish
peroxidas
conjug
alkalin
phosphatas
bdgalactosidaselabel
virusspecif
antibodi
well
wash
five
time
substrat
ml
ad
incub
dark
min
reaction
stop
ad
h
solut
absorb
read
nm
plate
seed
quadrupl
cell
monolay
log
dilut
test
drug
follow
infect
viru
h
incub
monolay
fix
glutaraldehyd
examin
virusspecif
protein
cell
surfac
elisa
perform
monoclon
antibodi
specif
protein
correspond
viru
protein
od
optic
densiti
measur
nm
concentr
calcul
reduct
od
valu
ec
extrapol
graphic
plot
follow
determin
si
ratio
cc
ec
result
express
percentag
virusinfect
cell
viru
control
test
drug
viru
pfuml
mix
incub
h
immedi
dilut
virusdrug
mixtur
final
inoculum
pfuwel
media
contain
fb
get
subtherapeut
concentr
mean
number
plaqu
control
mean
number
plaqu
sampl
ean
number
plaqu
control
test
drug
follow
mix
monolay
viru
inoculum
seed
use
plate
altern
add
virustest
drug
mix
dilut
incub
period
respect
cell
infect
allow
adsorb
h
discard
dilut
inoculum
wash
cell
pb
pour
overlay
medium
fb
incub
h
follow
plaqu
reduct
assay
count
viral
plaqu
number
obtain
infect
set
presenc
test
drug
compar
control
viral
attach
cell
surfac
carri
permit
bind
stop
viral
entri
elisa
briefli
incub
suscept
cell
cellswel
plate
allow
growth
overnight
cell
monolay
cool
cell
infect
viru
moi
use
heparin
presenc
test
drug
h
control
wash
well
icecold
pb
fix
prechil
paraformaldehyd
pb
h
ice
block
bsa
sampl
incub
h
primari
antibodi
pbst
pb
tween
along
bsa
well
wash
twice
pbst
bsa
pbst
twice
interv
shaker
mix
secondari
antibodi
pbst
bsa
incub
h
reaction
develop
two
compon
microwel
peroxidas
substrat
min
reaction
stop
phosphor
acid
absorb
measur
nm
valu
express
fold
chang
absorb
rel
mock
infect
control
lin
et
al
cell
monolay
cool
grown
plate
h
subsequ
infect
prechil
cell
pfuwel
incub
h
allow
viral
adsorpt
incub
infect
cell
monolay
presenc
test
drug
heparin
mgml
addit
min
facilit
penetr
extracellular
viru
inactiv
citrat
buffer
ph
min
cell
wash
pb
follow
overlay
dmem
contain
fb
h
incub
viral
plaqu
stain
count
lin
et
al
add
plate
cell
cellswel
plate
grown
overnight
confluenc
ml
viru
dilut
deae
dextran
final
concentr
mgml
adsorpt
h
co
incub
place
plate
rocker
prevent
cell
dri
add
fresh
medium
ml
contain
test
drug
well
incub
h
co
subconflu
growth
remov
media
add
fix
solut
ml
well
incub
min
room
temperatur
activ
decreas
dramat
fix
solut
left
min
discard
fix
solut
wash
cell
twice
pb
stain
incub
min
final
stain
plate
count
number
blue
syncytia
express
titrat
valu
number
stain
cell
multipli
viral
dilut
assay
applic
simian
immunodefici
viru
siv
simianhiv
carri
tzmbl
cell
reveal
reduct
tatinduc
luciferas
luc
report
gene
express
singl
round
viru
infect
place
tzmbl
cell
well
plate
incub
overnight
separ
vial
mix
moi
virion
test
drug
vehicl
h
add
tzmbl
cell
incub
h
wash
cell
cold
pb
add
fresh
media
test
drug
cultur
h
use
untreat
cell
neg
azidothymidin
azt
treat
cell
posit
control
wash
cell
twice
pb
lyse
lysi
buffer
add
supernat
substrat
analyz
luciferas
activ
optipl
use
fluorimet
result
express
percentag
inhibit
percent
inhibit
calcul
subtract
valu
wan
et
al
luminesc
experiment
group
test
drug
azt
lu
minesc
infect
cell
without
drug
b
cemgreen
fluoresc
protein
gpt
cellbas
assay
cemgfp
stabl
tcell
linecontain
plasmid
encod
gfp
suitabl
moi
cultur
postinfect
incub
cell
well
test
drug
day
use
azt
solvent
use
prepar
test
drug
control
lyse
virusinfect
cell
promega
cell
lysi
buffer
ml
transfer
cultur
plate
read
absorb
nm
excit
nm
emiss
fluorimet
result
express
percentag
inhibit
percent
inhibit
calcul
subtract
valu
place
hep
cell
suspens
viabl
cellsml
hep
seed
medium
microtit
plate
incub
day
discard
medium
wash
cell
monolay
warm
dpb
proper
well
add
assay
medium
contain
either
test
control
compound
desir
concentr
also
includ
well
hep
assay
medium
alon
viru
control
incub
day
day
wash
cell
warm
dpb
add
fresh
medium
contain
appropri
compound
well
h
transfer
supernat
vbottom
plate
remov
cellular
debri
centrifug
min
rpm
transfer
clarifi
supernat
new
vbottom
plate
store
quantif
hbv
dna
thaw
supernat
collect
add
denatur
solut
well
mix
incub
min
cut
nylon
membran
size
prepar
blot
wet
first
distil
water
hybrid
buffer
ssc
salin
sodiumcitr
dotblot
denatur
supernat
nylon
membran
direct
manufactur
wash
blot
neutral
solut
follow
ssc
remov
blot
rins
briefli
ssc
crosslink
dna
nylon
filter
uv
irradi
prehybrid
blot
h
hybrid
solut
prepar
probe
random
prime
use
portion
hbv
genom
templat
purifi
probe
clontech
chroma
spin
column
denatur
probe
boil
min
add
immedi
hybrid
solut
hybrid
nylon
filter
overnight
wash
nylon
filter
twice
ml
ssc
sd
sodium
dodecyl
sulfat
room
temperatur
min
twice
ml
ssc
sd
min
expos
nylon
filter
molecular
imag
screen
h
scan
phosphor
imag
obtain
data
determin
percent
inhibit
hbv
replic
subtract
background
valu
count
radiat
detect
nylon
filter
control
experiment
valu
divid
averag
valu
experiment
well
cell
treat
test
compound
averag
valu
viru
control
cell
treat
compound
tetracyclin
experi
multipli
number
king
ladner
mention
vitro
studi
list
tabl
drug
develop
program
includ
preclin
screen
immens
quantiti
chemic
specif
nonspecif
cytotox
numer
sort
cell
imper
show
potenti
therapeut
target
safeti
evalu
screen
plant
extract
pure
compound
investig
antivir
properti
signific
cytotox
measur
meyer
et
al
essenti
investig
item
establish
antivir
activ
concentr
accomplish
vivo
without
induc
toxic
cell
moreov
cell
cultur
display
antivir
activ
investig
item
aftereffect
host
cell
death
exposur
item
cytotox
test
util
seri
increas
concentr
antivir
product
determin
concentr
result
death
host
cell
valu
refer
median
cellular
cytotox
concentr
rel
effect
investig
product
inhibit
viral
replic
compar
induc
cell
death
defin
therapeut
select
index
valueec
valu
desir
high
therapeut
index
give
maximum
antivir
activ
minim
cell
toxic
accord
us
fda
guidelin
recommend
determin
valu
stationari
divid
cell
multipl
relev
human
cell
type
tissu
establish
potenti
cell
cycl
speci
tissuespecif
toxic
studi
determin
cytotox
therapeut
index
conduct
initi
phase
clinic
studi
number
advantag
vitro
test
use
cell
cultur
includ
gfp
fluoresc
experiment
group
fluoresc
infect
cell
without
test
drug
analysi
speci
specif
feasibl
use
small
amount
test
substanc
facil
mechanist
studi
guidanc
industri
confirm
cytotox
concentr
drug
concentr
select
antivir
studi
base
percentag
viabil
cell
use
studi
antivir
activ
cpe
inhibit
assay
viru
yield
assay
follow
mtt
assay
compound
cytotox
cell
inhibit
cell
prolifer
kill
cell
trypan
blue
dye
capabl
penetr
dead
cell
therefor
dead
cell
take
blue
stain
wherea
viabl
cell
method
give
exact
number
dead
viabl
cell
strober
protein
content
wide
use
estim
total
cellular
materi
use
growth
experi
colorimetr
method
estim
protein
sensit
cell
pellet
treat
cold
trichloroacet
acid
remov
amino
acid
pool
dissolv
alkalin
cupric
sulfat
folin
ciocalteau
phenol
reagent
folin
reagent
cupric
sulfat
togeth
react
amino
acid
give
blue
color
color
intens
proport
protein
concentr
measur
colorimetr
maya
et
al
proceed
techniqu
cell
well
trypsin
use
trypsin
transfer
eppendorf
tube
centrifug
rpm
min
obtain
pellet
cell
pellet
dissolv
naoh
dilut
tzmbl
cellbas
assay
hiv
cemgreen
fluoresc
protein
cellbas
assay
hiv
hep
assay
hbv
immunofluoresc
assay
enzymelink
immunosorb
assay
elisa
reduct
inhibit
virusspecif
polypeptid
synthesi
infect
cell
cultur
eg
viral
nucleic
acid
determin
uptak
radioact
isotop
label
precursor
viral
genom
copi
number
assay
valid
antivir
activ
viru
inactiv
assay
viru
adsorpt
assay
viru
attach
penetr
assay
n
test
drug
ad
protein
sampl
mix
left
min
test
reagent
ad
constant
mix
left
min
incub
absorb
read
nm
use
elisa
reader
biorad
color
develop
correl
cell
number
follow
cytotox
concentr
found
dye
exclus
techniqu
give
superfici
data
select
concentr
trypan
blue
dye
exclus
studi
use
estim
protein
mtt
diphenyl
tetrazolium
bromid
live
cell
enter
cell
enzym
succin
dehydrogenas
present
mitochondria
reduc
formazan
blue
product
color
intens
directli
proport
number
live
cell
perform
process
plate
seed
cell
cellswel
incub
h
h
medium
discard
drug
concentr
ad
incub
h
mgml
mtt
ad
incub
h
isopropyl
alcohol
ad
absorb
read
nm
elisa
plate
reader
biorad
result
tabul
percentag
growth
inhibit
calcul
use
follow
formula
concentr
test
drug
use
previou
experi
confirm
studi
mitochondri
synthesi
mtt
assay
formazan
blue
color
format
directli
proport
number
viabl
cell
therefor
absorb
read
nm
test
brine
shrimp
artemia
salina
egg
hatch
artifici
sea
water
gl
sea
salt
brine
shrimp
test
bst
bioassay
experi
perform
accord
procedur
describ
meyer
et
al
gener
sampl
test
drug
experi
prepar
methanol
solut
act
control
vehicl
h
incub
brine
shrimp
transfer
sampl
vial
use
pasteur
pipett
artifici
sea
water
ad
make
ml
sampl
vial
previous
prepar
dissolv
specif
concentr
test
drug
differ
dilut
solvent
evapor
overnight
survivor
count
h
lc
valu
confid
interv
determin
use
probit
analysi
describ
finney
control
vial
prepar
use
methanol
three
replic
prepar
concentr
test
drug
control
disk
prepar
use
methanol
replic
prepar
dose
level
begin
bioassay
brine
shrimp
egg
hatch
shallow
rectangular
dish
cm
condit
describ
literatur
except
natur
instead
artifici
seawat
use
ten
shrimp
select
transfer
sampl
vial
mean
dispos
pasteur
pipett
final
volum
vial
adjust
ml
use
natur
seawat
drop
dri
yeast
suspens
mg
ml
seawat
ad
food
vial
vial
maintain
illumin
survivor
count
aid
stereomicroscop
h
death
dose
level
control
determin
death
usual
observ
occur
control
h
brine
shrimp
test
bst
repres
rapid
inexpens
simpl
bioassay
test
plant
extract
lethal
case
correl
reason
well
cytotox
properti
mclaughlin
follow
procedur
meyer
et
al
lethal
test
drugsplant
extract
brine
shrimp
determin
lethal
concentr
test
drugsplant
extract
result
mortal
brine
shrimp
lc
confid
interv
determin
count
doserespons
data
transform
straight
line
mean
trend
line
fit
linear
regress
analysi
lc
deriv
bestfit
line
obtain
caffein
lc
meyer
et
al
use
posit
control
methanol
solvent
neg
control
bioassay
experi
current
scenario
viral
diseas
lethal
upsurg
new
viral
diseas
resist
exist
viral
infect
worldwid
current
access
antivir
howev
effect
exorbit
past
reach
major
individu
along
line
advanc
safe
effect
lowcost
antivir
medic
exampl
rt
inhibitor
among
top
prioriti
mani
viral
infect
yet
treatabl
high
death
rate
past
year
substanti
work
carri
regard
effect
medicin
plant
hiv
infect
premanathan
et
al
calabres
et
al
asr
et
al
increas
popular
overthecount
plant
product
contain
orthodox
drug
observ
main
focu
lower
advers
effect
associ
viral
infect
inclin
toward
synergist
interact
multipl
molecul
present
plant
extract
may
mostli
pharmacolog
mechan
combin
studi
antagonist
impact
remedi
disappoint
seen
chan
et
al
prerequisit
consid
signific
medicin
plant
identifi
standard
method
extract
prepar
suitabl
season
collect
plant
materi
detail
administr
chattopadhyay
et
al
lot
plant
extract
subsequ
formul
shown
signific
outcom
seem
ration
endors
idea
studi
medicin
plant
quest
find
potenti
antivir
